Chris Hurt
Papers
2
Total Citations
34
H-Index
2
About
Chris Hurt is a leading clinical researcher in head and neck oncology, with a focused expertise in human papillomavirus (HPV)-positive oropharyngeal cancer. His work is at the forefront of a critical shift in treatment: de-escalation therapy. Recognizing that standard treatments for HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) achieve high survival rates but inflict severe, long-term toxicities, Hurt has championed risk-stratified approaches. His landmark work, the PATHOS trial (cited 18 times), is a phase II/III study pioneering reduced-intensity adjuvant treatment following transoral surgery, aiming to preserve quality of life without compromising oncologic outcomes. Further demonstrating his impact, his 2024 study comparing transoral robotic surgery (TORS) and transoral laser microsurgery (TLM) (cited 16 times) provides crucial data on margin clearance and surgical efficacy. By challenging the "one-size-fits-all" paradigm, Hurt is not just treating cancer but redefining survivorship. His research is essential reading for any oncologist or surgeon seeking to balance cure with function, making him a key architect of the modern, more humane era of head and neck cancer care.
Research Focus
Key Achievements
Top Papers
- 1
- 2Transoral Laser or Robotic Surgery Outcomes for Oropharyngeal Carcinoma16 citations · 2024